Selexys Enrolls Sickle Cell Pain Trial

Selexys Pharmaceuticals Corporation, a privately held biopharmaceutical company that is developing therapies to treat inflammatory and thrombotic diseases, announced that enrollment has been initiated in SUSTAIN, a phase 2, multicenter, randomized, placebo-controlled, double-blind, 12-month study to assess safety and efficacy of the anti-P-selectin monoclonal antibody SelG1 with or without hydroxyurea therapy in sickle cell disease patients with sickle cell-related pain crises.

http://www.dddmag.com/news/2013/08/selexys-enrolls-sickle-cell-pain-trial?et_cid=3431535&et_rid=523035093&type=headline